Baron Funds, an investment management company, recently released its first-quarter 2025 investor letter for the Baron Discovery Fund. The letter, which can be downloaded from Insider Monkey, highlighted the fund’s performance during the quarter. Despite a 6.17% decline in the Institutional Shares, the fund outperformed the -11.12% return of the Russell 2000 Growth Index. The market saw a strong start in February but faltered due to concerns over Trump’s tariff enactment, which was perceived as inflationary and detrimental to economic growth. The decline worsened after April 2nd, leading to fears of a trade war and global recession.
One of the key stocks highlighted in the investor letter was Arcellx, Inc. (NASDAQ:ACLX). Based in Redwood City, California, Arcellx is focused on developing immunotherapies for patients with cancer and other incurable diseases. The stock had a one-month return of -7.30% and had gained 9.84% in value over the past 52 weeks. As of May 19, 2025, Arcellx closed at $58.51 per share with a market capitalization of $3.22 billion.
Baron Discovery Fund initiated a small position in Arcellx, Inc. (NASDAQ:ACLX) due to its collaboration with Gilead Sciences, Inc. in developing a next-generation CAR-T cell therapy called “Anito-cel” for multiple myeloma treatment. The fund sees potential in Arcellx’s safer CAR-T therapy, the sizable market opportunity, the company’s strong balance sheet with over $600 million in net cash, and a favorable manufacturing agreement with Gilead. This combination is expected to keep the company well-funded until profitability.
While Arcellx, Inc. (NASDAQ:ACLX) is not among the 30 most popular stocks held by hedge funds, Baron Discovery Fund remains optimistic about its growth potential. The fund believes that AI stocks offer greater promise for higher returns within a shorter timeframe. Investors interested in AI stocks with significant growth potential can explore opportunities highlighted in a report on undervalued AI stocks set for massive gains.
For further insights into Arcellx, Inc. (NASDAQ:ACLX), investors can refer to additional articles covering the company’s performance and views from Baron Health Care Fund. The fund has been holding Arcellx since 2023, indicating a long-term belief in the company’s prospects. Additionally, readers can access hedge fund investor letters from Q1 2025 for more investment insights.
In conclusion, Baron Discovery Fund’s initiation of a position in Arcellx, Inc. (NASDAQ:ACLX) reflects confidence in the company’s growth trajectory. As the market continues to evolve, investors can stay informed about potential investment opportunities by exploring various stock analyses and investor letters available on platforms like Insider Monkey.
